Jaktinib
Jaktinib[edit | edit source]
Jaktinib is a small molecule inhibitor that targets the Janus kinase (JAK) family of enzymes. It is primarily used in the treatment of various autoimmune diseases and certain types of cancer. Jaktinib functions by interfering with the JAK-STAT signaling pathway, which is crucial for the regulation of immune responses and cell growth.
Mechanism of Action[edit | edit source]
Jaktinib specifically inhibits the activity of JAK enzymes, which are intracellular, non-receptor tyrosine kinases. These enzymes play a key role in the signaling pathways of various cytokines and growth factors. By inhibiting JAKs, Jaktinib disrupts the phosphorylation and activation of signal transducer and activator of transcription (STAT) proteins, thereby modulating gene expression and reducing inflammatory responses.
Clinical Applications[edit | edit source]
Jaktinib is used in the management of several conditions, including:
In oncology, Jaktinib is being investigated for its potential to treat certain hematological malignancies and solid tumors by inhibiting aberrant JAK-STAT signaling that contributes to cancer cell proliferation and survival.
Side Effects[edit | edit source]
Common side effects of Jaktinib include:
Serious adverse effects may include:
- Thrombocytopenia
- Anemia
- Elevated liver enzymes
Pharmacokinetics[edit | edit source]
Jaktinib is administered orally and is absorbed in the gastrointestinal tract. It undergoes hepatic metabolism, primarily via the cytochrome P450 enzyme system, and is excreted in both urine and feces. The half-life of Jaktinib allows for once or twice daily dosing, depending on the therapeutic regimen.
Research and Development[edit | edit source]
Ongoing research is exploring the efficacy of Jaktinib in combination with other therapeutic agents, as well as its potential role in treating additional autoimmune and inflammatory conditions. Clinical trials are also assessing its long-term safety and effectiveness in diverse patient populations.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
